How to Help Your Patients Save Money on Motpoly XR: A Provider's Guide to Savings Programs

Motpoly XR (lacosamide extended-release) offers meaningful clinical advantages — once-daily dosing, potentially reduced peak-dose side effects — but its brand-only status and lack of a generic make it one of the more expensive AEDs on the market. With retail prices exceeding $1,500 per month, cost is frequently the primary barrier to access for your patients. This guide provides a systematic approach to connecting your patients with every available savings option.

Understanding the Cost Landscape for Motpoly XR

Before addressing solutions, it helps to understand the cost problem your patients face:

Retail cash price: Approximately $1,143–$1,565 per 30-day supply, depending on strength and pharmacy

Insurance placement: Typically Tier 3–4 on commercial formularies; often requires prior authorization

Medicare Part D: Coverage varies significantly by plan; may require PA; the $2,000 out-of-pocket cap under the Inflation Reduction Act (effective 2025) limits annual exposure for Medicare patients

Generic alternative: Generic lacosamide IR starting ~$22–$43 per 60 tablets — dramatically less expensive, but requires twice-daily dosing

Program 1: Aucta Pharmaceuticals Copay Savings Card

The Motpoly XR Copay Savings Card is the highest-impact tool for commercially insured patients:

Eligible patients: Commercially insured patients whose insurance covers Motpoly XR

Benefit: As little as $10 per 30-day supply

Not eligible: Medicare, Medicaid, CHIP, and other government-funded plans

Enrollment: Contact Aucta Pharmaceuticals at 1-800-655-9902, or ask your pharmacy. Enrollment typically takes minutes.

Workflow recommendation: Build copay card enrollment into your new patient medication initiation checklist. When starting a commercially insured patient on Motpoly XR, have your medical assistant initiate copay card enrollment before the patient leaves the office or call ends.

Program 2: Patient Assistance Program (PAP)

For patients who are uninsured or underinsured and meet income eligibility criteria, Aucta Pharmaceuticals' PAP may provide Motpoly XR at no cost or significantly reduced cost. Key points for your office workflow:

Income documentation is typically required — have patients gather recent tax returns or pay stubs before applying

The prescribing physician's signature is usually required on the PAP application

Processing time varies — provide samples to bridge patients during the application period

Contact Aucta Pharmaceuticals at 1-800-655-9902 for current PAP eligibility criteria and application materials

Additional PAP resources: NeedyMeds (needymeds.org) and RxAssist (rxassist.org) maintain searchable databases of all manufacturer PAP programs and can help your staff identify additional eligibility.

Strategy 3: Optimizing Insurance Coverage Through Prior Authorization

For patients whose insurance requires prior authorization, a well-documented PA submission is the gateway to the copay card working. Without PA approval, the drug may not be covered at all. High-yield PA documentation elements for Motpoly XR:

Medical necessity: Confirmed epilepsy diagnosis with ICD-10 code; seizure type (G40.x); current seizure frequency and control status.

Rationale for brand: Specific, patient-individualized reason for once-daily Motpoly XR over generic twice-daily lacosamide IR — adherence data, peak-dose CNS side effects with IR, patient-specific clinical factors.

Step therapy documentation: If step therapy is required, document any prior lacosamide IR trial — including dates, doses, and reasons for switching to XR formulation.

Clinical response: If the patient is already on Motpoly XR and responding well (seizure reduction or freedom), document this explicitly — continuing an effective medication has strong PA support.

Peer-to-peer review: If an initial PA is denied, request a peer-to-peer review between your office and the insurance plan's medical director. Neurologist-to-neurologist (or neurologist-to-medical director) reviews significantly improve approval rates for AED PAs.

38,224+ patients found their medications in stock

38K+

Find Motpoly XR In Stock Today →

Strategy 4: Consider Generic Lacosamide IR for Cost-Constrained Patients

For patients without commercial insurance (Medicare, Medicaid, uninsured) who cannot qualify for PAP or whose PA is denied, switching to generic lacosamide IR is often the most cost-effective path. Clinical considerations for this discussion:

Equivalent total daily dose — same amount of lacosamide, split into twice-daily dosing

Re-evaluate adherence risk — if once-daily dosing was prescribed specifically for adherence reasons, address this with the patient before switching

Monitor for peak-dose CNS side effects returning — patients who switched to XR for tolerability reasons may notice increased dizziness or double vision with twice-daily IR dosing

Strategy 5: Recommend Mail-Order for 90-Day Supplies

For commercially insured patients with PA approval and copay card enrollment, directing them to mail-order pharmacy for a 90-day supply can further reduce their effective per-dose cost while also eliminating the stocking access issues common at retail pharmacies. Most PBM mail-order programs (Express Scripts, CVS Caremark, OptumRx) are well-stocked for brand-name AEDs.

Skip the calls, skip the stress.

Find Motpoly XR In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Helping Patients Find It in Stock

Even when cost is resolved, patients may still struggle to find Motpoly XR in stock locally. Consider recommending medfinder for providers as a tool for your patients. medfinder calls pharmacies near the patient to identify which ones have Motpoly XR in stock, removing the burden of pharmacy calls from both patients and your staff.

For the broader provider availability picture, see: Motpoly XR Shortage: What Providers and Prescribers Need to Know in 2026.